Les travaux que nous finançons (en anglais seulement)

Funded projects
1 200+
Men's Health Partners
"We work closely with our global men's health partners to ensure collaboration, transparency and accountability for every project we fund. We monitor this through report cards which detail what we seek to achieve, key measures and the impact." - Owen Sharp, CEO
Prostate Cancer
"Together with the brightest minds in research, we aim to achieve significant breakthroughs in the hope of beating prostate cancer. Our disruptive funding approach identifies revolutionary ways to accelerate health outcomes by creating strong, global collaborative teams." Dr. Colleen Nelson, Global Scientific Chair.
Men's Health
"One Mo can help change the face of men’s health through the powerful conversations created globally during Movember. Men have the chance to confidently discuss men’s health with people around them, resulting in men taking action early, helping change and save lives." Paul Villanti, Executive Director, Programs
Mental health and suicide prevention
“We’re alarmed by the increasing number of men who take their own lives around the world. We are working to ensure all men and boys look after their mental health and are comfortable to reach out to others for support when they’re struggling.” 
Craig Martin, Global Director - Mental Health & Suicide Prevention programs
Testicular Cancer
“Despite being the 2nd most common cancer in young men, testicular cancer is often a forgotten cancer due to early detection and treatment. Our projects look at underinvested areas such as improving access to healthcare services and treatment options for relapse” Paul Villanti, Executive Director, Programs.

Distinguished Gentleman’s Ride Clinical Trial Awards 2016

Movember Funding to Date

AUD 19,412

What we seek to achieve

Clinical Trial Awards support clinical trials initiated in Australia that have the capacity to transform the clinical management of prostate cancer patients within the course of the trial and/or immediately after completion of the trial.

Distinguished Gentleman's Ride: AUD 230,588 Prostate Cancer Foundation of Australia: AUD $1,250,000
Implemented by
Movember Foundation and Prostate Cancer Foundation of Australia
Project start date
December 2017
Project Status
In Progress

About the project

Clinical Trials Awards will support clinical trials initiated in Australia that have the capacity to transform the clinical management of prostate cancer patients within the course of the trial and/or immediately post completion of the trial.
This funding scheme recognises the growing capacity for conducting clinical trials nationally and/or in collaboration with leading experts globally. It is envisaged that increasing the ability of Australia to conduct prostate cancer clinical trials will

•    Provide immediate benefit to men living with prostate cancer (i.e. patients would participate in these clinical trials and reap the benefit of treatments that are on the pipeline)
•    Increase participation in international clinical trials for which Australian patients would not otherwise be eligible 

Applications for the Clinical Trials Awards must focus on
•    Better tests for the diagnosis of prostate cancer
•    Biomarkers for monitoring of treatment
•    Better imaging
•    New and improved therapies
•    Survivorship and palliative care

Received applications were assessed by a multidisciplinary international expert panel.

This Award was granted to Associate Professor Michael Hofman from Peter MacCallum Centre, Melbourne, Victoria and is titled: A prospective phase II randomised controlled study of Lutetium-177 PSMA radionuclide therapy in metastatic prostate cancer patients.
PSMA is a substance on the surface of prostate cancer cells. Weakly radioactive substances can be attached to another molecule that can bind specifically to PSMA, and the radiation can be detected to help locate where in the body the cancer sits. This is called “PSMA PET scanning.” It is also possible to attach a much stronger type of radioactive atom, with the idea of killing cells like prostate cancer cells that have PSMA on their surface. Initial studies with this approach have given promising results but it is necessary to study it further in order to determine how effective and safe it is, and how it compares to currently available treatments. Some of the key questions will be: 
•    how the lutetium-177 PSMA affects the survival of these men; 
•    its effects on stopping the cancer from progressing; 
•    whether it can in fact shrink cancer;
•    what the side effects are;
•    whether it has beneficial effects on the quality of life of these men, and 
•    whether this new treatment is cost effective. 
This trial aims to establish where lutetium-177 PSMA will fit into the treatment sequence and is anticipated to have a substantial influence on clinical practice.

Page 1 of 22